NOVABAY PHARMACEUTICALS, INC. NBY Income Statement

Novabay pharmaceuticals, inc. (NBY)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Sales:
Total sales, net
7,000	6,599	8,520	10,047	11,052	12,508	15,199	16,148	17,476	18,230	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product cost of goods sold
1,978	1,738	1,586	1,517	1,593	1,503	2,039	2,228	2,447	2,784	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product revenue, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,158	7,032	5,309	4,146	2,649	1,534	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License, collaboration and distribution revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	3,806	6,388	6,454	6,855	8,550	9,460	0	-	0	0	-	-	-
License and collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Other revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	297	185	253	235	331	329	354	370	3,331	3,334	3,273	3,254	182	142	116	78	55	0	0	-	0	-	-	-	-
Total sales, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,455	7,217	5,562	4,381	2,898	1,821	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-
Product cost of goods sold
-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,247	1,950	1,724	1,261	966	739	504	486	271	272	270	162	0	0	0	-	-	-	-	-	-	-	-	-	-
Gross profit
5,022	4,861	6,934	8,530	9,459	11,005	13,160	13,920	15,029	15,446	13,376	12,678	11,438	9,433	7,208	5,267	3,838	3,120	2,371	1,550	900	568	3,590	3,436	3,332	3,315	0	0	0	-	-	-	-	-	-	-	-	-	-
Total other revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	3,988	6,530	6,570	6,933	7,063	6,193	9,849	11,019	11,875	11,651	0	0	0
Operating expenses:
Research and development
108	184	273	269	298	259	298	385	394	410	420	292	500	1,371	2,440	3,999	5,078	5,728	6,888	7,637	8,518	9,483	11,184	11,385	12,084	12,461	10,494	10,495	9,936	9,275	9,355	8,864	9,255	9,911	9,957	10,063	0	0	0
Sales and marketing
6,796	8,767	9,796	11,482	12,924	12,789	12,902	12,968	13,367	13,711	13,561	12,928	12,405	11,809	11,923	12,295	11,753	10,523	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
4,982	5,310	5,638	5,649	5,811	5,828	5,828	6,795	7,170	8,636	9,128	9,083	8,641	7,235	8,066	7,481	8,134	8,006	0	0	0	-	-	-	-	-	-	0	0	-	5,642	5,505	5,455	5,429	5,417	5,931	0	0	0
Sales, general and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,797	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
11,886	14,261	15,707	17,400	19,033	18,876	19,028	20,148	20,931	22,757	23,109	22,303	21,546	20,415	22,429	23,775	24,965	24,257	22,066	20,010	18,287	17,472	17,646	17,461	18,552	18,801	17,454	17,164	15,928	15,248	14,997	14,369	14,710	15,340	15,374	15,994	0	0	0
Operating loss
-6,864	-9,400	-8,773	-8,870	-9,574	-7,871	-5,868	-6,228	-5,902	-7,311	-9,733	-9,625	-10,108	-10,982	-15,221	-18,508	-21,127	-21,137	-19,795	-18,560	-17,487	-16,904	-16,844	-15,713	-16,077	-15,486	-13,462	-10,586	-9,311	-8,309	-7,934	-8,176	-4,861	-4,321	-3,499	-4,343	0	0	0
Non-cash gain (loss) on changes in fair value of warrant liability
-943	-749	-1,276	-63	-1,040	-1,311	-1,371	-823	-348	101	2,172	2,315	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on changes in fair value of embedded derivative liability
0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non cash loss on changes in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,730	-	624	381	1,178	1,664	1,940	1,178	485	-555	-645	430	954	1,439	1,255	0	0	-	0	-	-	-	-
Other expense, net
-1,551	-1,425	-1,160	-437	-45	19	16	15	14	12	10	3	-25	-68	12	-15	-13	17	-64	-35	44	48	51	58	0	-	0	0	-	-155	11	34	-4	-30	-32	-44	0	0	0
Loss before provision for income taxes
-7,046	-9,652	-8,234	-9,490	-8,579	-6,541	-4,481	-5,390	-5,540	-7,400	-11,931	-12,172	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss before provision for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19,410	-	-19,235	-18,214	-16,265	-15,192	-14,863	-14,489	-15,598	-16,040	-14,259	-10,328	-8,507	-7,025	-8,306	-8,281	-5,632	-5,083	-3,078	-4,387	0	0	0
Provision for income taxes
-	6	4	4	0	-	-	0	-	3	1	1	3	2	-6	-4	0	2	10	18	0	-	0	0	-	1	-4	-1	-2	2	-1	-2	-4	2	0	0	0	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,194	-14,863	-14,492	-15,598	-16,042	-14,255	-10,327	-8,505	-7,027	-8,305	-8,279	-5,628	-5,085	-3,099	-4,403	0	0	0
Change in Unrealized gains on available for sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15	3	6	-2	-2	16	43	31	31	0	0	0	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,179	-14,860	-14,486	-15,600	-16,044	-14,239	-10,284	-8,474	-6,996	0	0	0	-	-	-	-	-	-
Net loss and comprehensive loss
-7,051	-9,658	-8,240	-9,496	-8,584	-6,545	-4,484	-5,393	-5,542	-7,403	-9,844	-11,133	-12,085	-13,151	-15,707	-17,213	-19,410	-18,973	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.34	-0.36	-1.24	-1.08	-1.77	-1.84	-2.13	-7.43	-0.08	-0.06	-0.08	-10.19	-0.10	-0.11	-0.11	-	-	-0.08	-0.09	-	-	0.02	-0.08	-0.07	-0.05
Change in unrealized gains (losses) on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-
Total comprehensive income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)
-0.06	-0.08	-0.01	-0.14	-0.25	-0.08	-0.09	-0.09	-0.13	0.05	-0.16	-0.11	-0.26	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-	0.00	-	-	-	-
Net loss per share attributable to common stockholders (diluted) (in dollars per share)
-	-	-0.02	-0.14	-	-0.09	-0.11	-0.12	-0.14	0.05	-0.16	-0.11	-0.26	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-	0.00	-	-	-	-
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,913	7,407	4,086	5,523	2,957	2,653	2	-138,986	50,821	50,767	45,338	-105,381	37,467	37,266	36,756	-	-	-	-	-	-	-	-	-	-
Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders (basic and diluted) (in shares)
27,978	27,762	23,096	18,613	17,093	17,100	17,089	17,089	16,406	15,380	15,324	15,308	15,284	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28,861	-	-	-	27,902	-	-	-	-
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (diluted) (in shares)
-	-	23,213	18,613	-	17,122	17,148	17,292	16,670	15,380	15,324	15,308	15,284	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29,284	28,671	28,572	28,282	27,902	23,480	23,428	23,335	23,315
Product [Member]
Total sales, net
6,998	6,556	8,458	9,985	10,990	12,474	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product and Service, Other [Member]
Total sales, net
-	43	62	62	62	34	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-